PropertyValue
?:abstract
  • Abstract: With over 100,000 deaths worldwide from coronavirus disease 2019 (COVID-19), it is incumbent on researchers to accelerate clinical trials of any readily available and potentially acceptably safe therapies that could reduce the rising death toll, writes researchers led by Marc Feldmann at Oxford University Botnar Research Centre, in The Lancet Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gains access to host cells via angiotensin-converting enzyme 2, which is expressed in the type II surfactant-secreting alveolar cells of the lungs
?:creator
?:journal
  • Medical_Brief
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Trials of anti-tumour necrosis factor therapy for COVID-19 ‘urgently needed’
?:type
?:who_covidence_id
  • #1033917
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/s7e35dlo>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/s7e35dlo>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all